Considerations for the real‐world management of ARIA from the aducanumab phase 3 studies EMERGE and ENGAGEPatrick Burkett, Samantha Budd Haeberlein, Sami Fam et al.|Alzheimer s & Dementia|2021Cited by 1
Considerations for the Real-World Management of ARIA From the Aducanumab Phase 3 Studies EMERGE and ENGAGE (P1-1.Virtual)Richard E. Hughes, Samantha Budd Haeberlein, Patrick Burkett et al.|Neurology|2022Cited by 0
Dimethyl Fumarate Exerts Selective Effects on Key B Cell Subsets and IgG Levels Which May Contribute to its Therapeutic Benefit in MS While Maintaining Protective Humoral Immunity (P2.2-069)Amit Bar‐Or, Sami Fam, Devangi Mehta et al.|Neurology|2019Cited by 0